ATLAS News · Companies

Novo Nordisk: FDA rejects weekly insulin, company pledges $200 million

Published November 13, 2026 · 3 sources

Reports say the FDA rejected Novo Nordisk's once-weekly basal insulin application, while the company pledged $200 million and raised guidance.

What happened

ad-hoc-news.de reports that the FDA rejected Novo Nordisk's application for a once-weekly basal insulin, describing it as a setback for the company's US pipeline.

Traders Union reports that the company pledged $200 million to the World Diabetes Foundation and raised its full-year guidance. The outlet says the shares rose 2.19% on the day, citing renewed buying interest.

In a separate report, ad-hoc-news.de says the stock faces an FDA warning related to a rare eye risk. The sources do not give further details on that warning.

Context

Novo Nordisk is a Danish pharmaceutical company with a major focus on diabetes care, and its US-listed shares trade under the ticker NVO.

Why it matters

Regulatory decisions, safety warnings, philanthropic commitments and guidance changes can each affect how investors view Novo Nordisk's outlook, though the sources do not quantify any impact.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Novo Nordisk A/SNVO

+2.41%

Healthcare · NYSE

Live price

$41.63▲ +2.41%

live price · USD

Close on November 13: $41.63+2.41% vs. previous close ($40.65)
Fair value (ATLAS): $81.19Fair range: $67.57 to $106.94The price ($41.63) is 48.7% below that figure.
Chance of a rise in 1 month: 50%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $39.22 and $44.25; 9 in 10, between $35.25 and $49.24.

See the full ATLAS analysis of Novo Nordisk A/S →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

Novo Nordisk stock: FDA rejects weekly basal insulin bid · ad-hoc-news.de · November 13, 2026
Novo Nordisk stock rises over 2% as company pledges $200 million to World Diabetes Foundation and lifts guidance · Traders Union · November 13, 2026
Novo Nordisk stock faces FDA warning over rare eye risk · ad-hoc-news.de · November 14, 2026

Latest market news · Markets today on ATLAS · Novo Nordisk A/S

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer